Work

Successful ruxolitinib administration for a patient with steroid‐refractory idiopathic pneumonia syndrome following hematopoietic stem cell transplantation: A case report and literature review

Year: 2021

Type: article

Study design: Case Report

Abstract: Idiopathic pneumonia syndrome (IPS) is an acute lung complication observed after the early posthematopoietic stem cell transplantation (HSCT) period. Ruxolitinib was effective for a patient with myelodysplastic syndrome who developed severe IPS after second HSCT. No severe adverse effects were observed. Ruxolitinib may be an alternative choice for HSCT-related IPS.

Source: Clinical Case Reports

DOI: 10.1002/ccr3.5242

Authors: Dan Tomomasa, Takeshi Isoda, Noriko Mitsuiki, Motoi Yamashita, Aoi Morishita, Takahiro Tomoda, Tsubasa Okano, Akifumi Endo, Takahiro Kamiya, Masakatsu Yanagimachi, Kohsuke Imai, Hirokazu Kanegane, Masatoshi Takagi, Tomohiro Morio

Institutions: Tokyo Medical and Dental University, Kanagawa Children's Medical Center

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,210

Funders: Tokyo Medical and Dental University, Japan Society for the Promotion of Science

Awards: Investigation for control of enhancer activity by non-coding RNA transcription and mechanism of developing primary immunodeficiency and oncogenesis under the disrupted non-coding transcription., Mechanistic Insights into Non-Coding RNA Transcription and Super-Enhancer Activation via Control Region Mutations, Development of a new CAR-NK cell therapy using activated NK cells

OpenAlex ID: W4200000978

FWCI: 0.809

Cites: 34

Cited by: 12

Related to: 10